



Section 7 – Regulation FD

Item 7.01 Regulation FD Disclosure.

On September 28, 2015, Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing preliminary clinical data from ongoing Phase I studies of its anti-cancer compounds Supinoxin™ and RX-3117 were presented in two poster presentations at the joint 18<sup>th</sup> ECCO-40<sup>th</sup> ESMO European Cancer Congress 2015.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	Rexahn Pharmaceuticals, Inc. press release dated September 28, 2015, announcing the presentation of preliminary clinical data.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REXAHN PHARMACEUTICALS, INC.

Date: September 28, 2015 /s/ Tae Heum Jeong

Tae Heum Jeong

Senior Vice President of Finance and Chief Financial Officer

---